Sonnet Biotherapeutics Holdings Inc expected to post a loss of 16 cents a share - Earnings Preview

Sonnet Biotherapeutics Holdings

13/12/2021 13:32

* Sonnet Biotherapeutics Holdings Inc  SONN.OQ   SONN.O  is
expected to report results on December 15 (estimated).
​* Refinitiv's mean analyst estimate for Sonnet Biotherapeutics
Holdings Inc is for a loss of 16 cents per share. 
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
​
* Wall Street's median 12-month price target for Sonnet
Biotherapeutics Holdings Inc is $6.5​, about 91.7% above​ its
last closing price of $0.54. ​​​
This summary was machine generated December 13 at 13:32 GMT. 
All figures in US dollars  unless otherwise stated